EXELExelixis, Inc.

$59.86+49% 1Y

$59.86

$34.5452 weeks$59.86

Latest close: a new 52-week highOct 9, 2026what changed →

EXEL in its own filings

Nothing in EXEL's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

522

Events found in the filings · across 2,513 filings · the record starts in 2000

Hard flags: none
Hard flags
Most recent filing: Sep 11, 2026
Most recent filing · Form 8-K
Record starts: Apr 24, 2000
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 3, 2026
SEC comment-letter activity29 occurrences: 2024-05-21

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 11, 2026Today, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic …Other event · Form 8-K
Aug 31, 2026On August 31, 2026, Exelixis, inc. (Exelixis) announced that the U.S. Court of Appeals for the Federal Circuit (Court of Appeals) issued a decision in Exelixis, Inc. v.Other event · Form 8-K
Aug 5, 2026SVP, Strategy & Investor Relations.Earnings release · press release
May 29, 2026On May 26, 2026, at the 2026 Annual Meeting of Stockholders (the Annual Meeting) of Exelixis, Inc. (Exelixis), Exelixis’ stockholders, upon recommendation of Exelixis’ Board of Directors, approved the amendment and restatement of the Exelixis, Inc. 2017 Equity Incentive Plan (as so amended and restated, the 2017 Plan)Director or officer change · Form 8-K
May 5, 2026Stock Repurchase On May 5, 2026, Exelixis announced that the Board of Directors authorized the repurchase of up to an additional $750 million of its common stock by December 31, 2027.Earnings release · Form 8-K
Feb 10, 2026SVP, Strategy and Investor Relations.Earnings release · press release
Jan 12, 2026SVP, Strategy and Investor Relations.Earnings release · press release
Nov 7, 2025On November 4, 2025, Jeffrey Hessekiel, J.D., Executive Vice President and General Counsel of Exelixis, Inc. (the Company) notified the Company of his intention to resign from the Company, effective in November 2025, and he will cease serving in his role as General Counsel effective as of November 7, 2025.Director or officer change · Form 8-K
Nov 4, 2025Stock Repurchase On November 4, 2025, Exelixis announced that the Board of Directors authorized the repurchase of up to $750 million of its common stock before December 31, 2026.Earnings release · Form 8-K